Abstract:Vaccines utilizing modified messenger RNA (mRNA) technology have shown robust protective efficacy against SARS-CoV-2 in humans. As the virus continues to evolve in both human and non-human hosts, risk remains that the performance of the vaccines can be compromised by new variants with strong immune escape abilities. Here we present preclinical characterizations of a novel bivalent mRNA vaccine RQ3025 for its safety and effectiveness in animal models. The mRNA sequence of the vaccine is designed to incorporate common mutations on the SARS-CoV-2 spike protein that have been discovered along the evolutionary paths of different variants. Broad-spectrum, high-titer neutralizing antibodies against multiple variants were induced in mice (BALB/c and K18-hACE2), hamsters and rats upon injections of RQ3025, demonstrating advantages over the monovalent mRNA vaccines. Effectiveness in protection against several newly emerged variants is also evident in RQ3025-vaccinated rats. Analysis of splenocytes derived cytokines in BALB/c mice suggested that a Th1-biased cellular immune response was induced by RQ3025. Histological analysis of multiple organs in rats following injection of a high dose of RQ3025 showed no evidence of pathological changes. This study proves the safety and effectiveness of RQ3025 as a broad-spectrum vaccine against SARS-CoV-2 variants in animal models and lays the foundation for its potential clinical application in the future.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a broad - spectrum bivalent mRNA vaccine (RQ3025) to deal with various variants of the SARS - CoV - 2 virus, especially those new variants with strong immune escape capabilities. Specifically, the study aims to evaluate the safety and efficacy of this new bivalent mRNA vaccine in animal models. ### Main problems 1. **Immune escape**: As the SARS - CoV - 2 virus continues to evolve in human and non - human hosts, newly emerging variants may have strong immune escape capabilities, thereby weakening the effectiveness of existing monovalent mRNA vaccines. 2. **Broad - spectrum protection**: Develop a vaccine that can provide broad - spectrum protection against multiple SARS - CoV - 2 variants to deal with new variants that may emerge in the future. 3. **Safety**: Ensure that the new bivalent mRNA vaccine does not cause pathological changes or other adverse reactions in animal models. ### Research methods To achieve the above goals, researchers designed an mRNA sequence containing common mutation sites, which were discovered in the evolutionary paths of different SARS - CoV - 2 variants. The safety and efficacy of the RQ3025 vaccine were studied by conducting inoculation experiments in mice (BALB/c and K18 - hACE2), hamsters and rats. ### Key results - **Broad - spectrum neutralizing antibodies**: After inoculation with RQ3025, high - titer broad - spectrum neutralizing antibodies against multiple SARS - CoV - 2 variants were produced in mice, hamsters and rats, showing an advantage over monovalent mRNA vaccines. - **Cellular immune response**: Through the analysis of cytokines derived from splenocytes of BALB/c mice, it was found that RQ3025 induced a Th1 - skewed cellular immune response. - **Safety**: In rats inoculated with a high dose of RQ3025, no pathological changes were found in the histological analysis of multiple organs. ### Conclusion This study shows that RQ3025, as a broad - spectrum bivalent mRNA vaccine, exhibits good safety and efficacy in animal models and can effectively combat multiple SARS - CoV - 2 variants. This lays the foundation for its future application in the clinic. By solving these problems, researchers hope to provide a more effective preventive means in the face of the continuously evolving SARS - CoV - 2 virus.

Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studies

A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants

Preclinical evaluation of RQ3013, a broad-spectrum mRNA vaccine against SARS-CoV-2 variants

RBD-mRNA Vaccine Induces Broadly Neutralizing Antibodies Against Omicron and Multiple Other Variants and Protects Mice from SARS-CoV-2 Challenge.

Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models

Broad protection and respiratory immunity of dual mRNA vaccination against SARS-CoV-2 variants

RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice

Universal protection against SARS-CoV-2 viruses by multivalent mRNA vaccine in mice

Multivalent mRNA Vaccine Elicits Broad Protection against SARS-CoV-2 Variants of Concern

Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models

Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants

A Delta-Omicron Bivalent Subunit Vaccine Elicited Antibody Responses in Mice against Both Ancestral and Variant Strains of SARS-CoV-2

A protein vaccine of RBD integrated with immune evasion mutation shows broad protection against SARS-CoV-2

A Unique mRNA Vaccine Elicits Protective Efficacy against the SARS-CoV-2 Omicron Variant and SARS-CoV

A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2

Trivalent mRNA Vaccine against SARS-CoV-2 and Variants with Effective Immunization

Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates

Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern

Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original Mrna Vaccine Booster

Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern